CLINICAL TRIALS PROFILE FOR VELTASSA
✉ Email this page to a colleague
All Clinical Trials for Veltassa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00868439 ↗ | Evaluation of Patiromer in Heart Failure Patients | Completed | Medpace, Inc. | Phase 2 | 2009-04-01 | The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure. |
| NCT00868439 ↗ | Evaluation of Patiromer in Heart Failure Patients | Completed | Relypsa, Inc. | Phase 2 | 2009-04-01 | The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure. |
| NCT01130597 ↗ | Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease | Completed | Relypsa, Inc. | Phase 2 | 2010-05-01 | The purpose of this study was to evaluate the feasibility of individualized titration of patiromer according to serum potassium. This study also assessed the safety and tolerability of patiromer and the effects of patiromer on serum potassium in heart failure (HF) participants with chronic kidney disease (CKD). |
| NCT01371747 ↗ | Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) | Completed | Relypsa, Inc. | Phase 2 | 2011-06-01 | This study determined the optimal starting dose of patiromer in treating hyperkalemia in participants with hypertension and diabetic nephropathy who were already receiving ACEI and/or ARB drugs, with or without spironolactone. This study also evaluated the efficacy and safety of patiromer and the long term use of patiromer. |
| NCT01810939 ↗ | A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) | Completed | Relypsa, Inc. | Phase 3 | 2013-02-01 | The purpose of this study was to evaluate the efficacy and safety of patiromer (investigational drug) in the treatment of hyperkalemia (high serum potassium). The study also evaluated the effect of withdrawing patiromer treatment and assessed whether chronic treatment with patiromer prevented the recurrence of hyperkalemia. The safety of patiromer treatment was also evaluated. |
| NCT02033317 ↗ | An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis | Terminated | Relypsa, Inc. | Phase 2 | 2008-08-01 | This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Veltassa
Condition Name
Clinical Trial Locations for Veltassa
Trials by Country
Clinical Trial Progress for Veltassa
Clinical Trial Phase
Clinical Trial Sponsors for Veltassa
Sponsor Name
